247 related articles for article (PubMed ID: 12594810)
21. Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.
Song MM; Makena MR; Hindle A; Koneru B; Nguyen TH; Verlekar DU; Cho H; Maurer BJ; Kang MH; Reynolds CP
Anticancer Drugs; 2019 Feb; 30(2):117-127. PubMed ID: 30272587
[TBL] [Abstract][Full Text] [Related]
22. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids.
Cuperus R; Tytgat GA; Leen R; Brites P; Bras J; Caron HN; Van Kuilenburg AB
Int J Oncol; 2008 May; 32(5):1011-9. PubMed ID: 18425327
[TBL] [Abstract][Full Text] [Related]
23. A novel metastatic animal model reflecting the clinical appearance of human neuroblastoma: growth arrest of orthotopic tumors by natural, cytotoxic human immunoglobulin M antibodies.
Engler S; Thiel C; Förster K; David K; Bredehorst R; Juhl H
Cancer Res; 2001 Apr; 61(7):2968-73. PubMed ID: 11306475
[TBL] [Abstract][Full Text] [Related]
24. p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action.
Takahashi N; Watanabe Y; Maitani Y; Yamauchi T; Higashiyama K; Ohba T
Int J Cancer; 2008 Feb; 122(3):689-98. PubMed ID: 17955489
[TBL] [Abstract][Full Text] [Related]
25. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
Ohlmann CH; Jung C; Jaques G
Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800
[TBL] [Abstract][Full Text] [Related]
26. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
27. Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an
Orienti I; Farruggia G; Nguyen F; Guan P; Calonghi N; Kolla V; Chorny M; Brodeur GM
Int J Nanomedicine; 2020; 15():6873-6886. PubMed ID: 32982239
[TBL] [Abstract][Full Text] [Related]
28. Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles.
Okuda T; Kawakami S; Higuchi Y; Satoh T; Oka Y; Yokoyama M; Yamashita F; Hashida M
Int J Pharm; 2009 May; 373(1-2):100-6. PubMed ID: 19429294
[TBL] [Abstract][Full Text] [Related]
29. Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
Fang H; Harned TM; Kalous O; Maldonado V; DeClerck YA; Reynolds CP
Clin Cancer Res; 2011 Nov; 17(22):7093-104. PubMed ID: 21933888
[TBL] [Abstract][Full Text] [Related]
30. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
31. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
32. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.
Cheung BB; Tan O; Koach J; Liu B; Shum MS; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M; Norris MD; Kavallaris M; Liu T; O'Neill GM; Marshall GM
Mol Oncol; 2015 Aug; 9(7):1484-500. PubMed ID: 25963741
[TBL] [Abstract][Full Text] [Related]
33. A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model.
Orienti I; Nguyen F; Guan P; Kolla V; Calonghi N; Farruggia G; Chorny M; Brodeur GM
Drug Des Devel Ther; 2019; 13():4305-4319. PubMed ID: 31908416
[TBL] [Abstract][Full Text] [Related]
34. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
35. Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models.
Nguyen TH; Koneru B; Wei SJ; Chen WH; Makena MR; Urias E; Kang MH; Reynolds CP
Mol Cancer Ther; 2019 Dec; 18(12):2270-2282. PubMed ID: 31484706
[TBL] [Abstract][Full Text] [Related]
36. Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
Di Vinci A; Geido E; Infusini E; Giaretti W
Int J Cancer; 1994 Nov; 59(3):422-6. PubMed ID: 7927952
[TBL] [Abstract][Full Text] [Related]
37. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
[TBL] [Abstract][Full Text] [Related]
38. The Pyrazolo[3,4-
Rango E; Pastorino F; Brignole C; Mancini A; Poggialini F; Di Maria S; Zamperini C; Iovenitti G; Fallacara AL; Sabetta S; Clementi L; Valoti M; Schenone S; Angelucci A; Ponzoni M; Dreassi E; Botta M
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327462
[TBL] [Abstract][Full Text] [Related]
39. p75 neurotrophin receptor and fenretinide-induced signaling in neuroblastoma.
Ganeshan VR; Schor NF
Cancer Chemother Pharmacol; 2014 Feb; 73(2):271-9. PubMed ID: 24253178
[TBL] [Abstract][Full Text] [Related]
40. Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration.
Orienti I; Zuccari G; Bergamante V; Carosio R; Gotti R; Cilli M; Montaldo PG
Biomacromolecules; 2007 Oct; 8(10):3258-62. PubMed ID: 17883277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
